Explore evidence

1.9 %HIV prevalence in the West and Central African region is 1.9%.

Côte d'IvoireVIH/sidapublished 2020International journal of infectious diseases : IJID : official publication of the Internateurope_pmcdocument of 3 observations

78 %The median self-reported adherence rate to highly active antiretroviral therapy (HAART) was 78% among HIV-infected adults followed in field conditions in Abidjan.

Côte d'IvoireVIH/sidapublished 2007Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 2 observationsDOI 10.1097/qai.0b013e31805d8ad0

11 casesOf the 1023 HIV-1-infected adults randomized in the Temprano deferred-ART group, 11 (1.1%) were viremic controllers.

Côte d'IvoireVIH/sidapublished 2022AIDS (London, England)europe_pmcdocument of 3 observations

463 patientsAmong dually seropositive patients, 463 were on antiretroviral therapy (ART).

Côte d'IvoireVIH/sidapublished 2013PloS oneeurope_pmcdocument of 14 observations

25 %Nine out of 36 HIV-infected patients died, representing a mortality rate of 25%.

Côte d'IvoireVIH/sidaobserved January 2005-July 2015published 2018The Pan African medical journaleurope_pmcdocument of 9 observations

7 casesOf the 1023 HIV-1-infected adults randomized in the Temprano deferred-ART group, seven (0.7%) were elite controllers.

Côte d'IvoireVIH/sidapublished 2022AIDS (London, England)europe_pmcdocument of 3 observations

25 monthsThe median follow-up duration was 25 months (interquartile range 19–31 months) among HBeAg-negative HIV/HBV co-infected patients in Côte d'Ivoire.

Côte d'Ivoirehépatite B · VIH/sidapublished 2019Transactions of the Royal Society of Tropical Medicine and Hygieneeurope_pmcdocument of 4 observations

14,480 deaths_per_yearAcross setting-scenarios, there was a mean of 14,480 deaths per year over 50 years with the switch policy in a setting with an adult population of 10 million in 2024.

Côte d'IvoireVIH/sidapublished 2025The lancet. HIVeurope_pmcdocument of 6 observations

68.6 %68.6% of the patients were on antiretroviral therapy (ART).

Côte d'IvoireVIH/sidaobserved 2012published 2014Journal of the International AIDS Societyeurope_pmcdocument of 8 observations

25 %At month 12 after ART initiation, 25% of patients in active follow-up had detectable viral loads.

Côte d'IvoireVIH/sidapublished 2013Journal of acquired immune deficiency syndromes (1999)europe_pmcdocument of 11 observations

26.6 %Only 34 patients (26.6%) returned for clinical and biological post-exposure follow-up with HIV control at third month, without documented seroconversion.

Côte d'IvoireVIH/sidaobserved 2000-2007published 2010Medecine et maladies infectieuseseurope_pmcdocument of 13 observations

4 yearsMedian duration of antiretroviral therapy was 4 years.

Côte d'IvoireVIH/sidapublished 2014AIDS (London, England)europe_pmcdocument of 9 observations

2.9 log10 copies/million PBMCThe median pre-antiretroviral treatment HIV-1 DNA level was 2.9 log10 copies per million PBMC among 1013 patients in the Temprano trial conducted in Côte d'Ivoire.

Côte d'IvoireVIH/sidapublished 2022BMC infectious diseaseseurope_pmcdocument of 3 observationsDOI 10.1186/s12879-022-07082-2

31.8 %Among 66 HBsAg-positive patients, 31.8% had HBeAg-positive hepatitis.

Côte d'Ivoirehépatite B · VIH/sidaobserved 2006published 2012World journal of hepatologyeurope_pmcdocument of 13 observations

185 cells/μlThe median baseline CD4 cell count among HIV-2-infected individuals initiating antiretroviral therapy was 185 cells/μl.

Côte d'IvoireVIH/sidapublished 2016AIDS (London, England)europe_pmcdocument of 6 observations

Early antiretroviral therapy decreased the risk of AIDS, tuberculosis, invasive bacterial diseases and Kaposi's sarcoma considered separately.

Côte d'Ivoireinvasive bacterial diseases · Kaposi's sarcoma · tuberculose · VIH/sidapublished 2016AIDS research and therapyeurope_pmcdocument of 5 observations

8,427 participantsThree randomized controlled trials — HPTN 052, Temprano ANRS 12136 and START — recruited 8427 HIV-infected adults in 37 countries.

Côte d'IvoireVIH/sidapublished 2016AIDS research and therapyeurope_pmcdocument of 5 observations

24 per_100_person_yearsThe incidence rate of serious HIV-related events was 24.0 per 100 person-years among HIV-HBV co-infected patients with baseline HBV-replication > 10,000 copies/mL.

Côte d'Ivoirehépatite B · VIH/sidapublished 2017The American journal of tropical medicine and hygieneeurope_pmcdocument of 7 observationsDOI 10.4269/ajtmh.16-1016

15 %Among hospitalized HIV-positive adults in West Africa, pneumonia was diagnosed in 15% of patients.

Côte d'Ivoirepneumonie · VIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797

7.2 %At baseline, 7.2% of participants were obese.

Côte d'IvoireVIH/sidapublished 2016AIDS research and therapyeurope_pmcdocument of 9 observations

2.1 hazard_ratioIn univariate analysis, the hazard ratio of death was 2.10 (95% CI, 1.38–3.21) for patients with HIV-1 RNA ≥5 log10 copies/ml vs. others in the Temprano trial.

Côte d'IvoireVIH/sidapublished 2020EBioMedicineeurope_pmcdocument of 7 observations

19.2 %In a cohort of HIV-infected patients of sub-Saharan African origin, the cumulative incidence of insulin resistance was 19.2% after 3 years of combined antiretroviral therapy.

Côte d'Ivoireinsulin resistance · VIH/sidapublished 2015AIDS research and human retroviruseseurope_pmcdocument of 7 observations

12.9 %A total of 4 (12.9%) HIV-2 patients were lost to follow-up.

Côte d'IvoireVIH/sidapublished 2020PloS oneeurope_pmcdocument of 13 observationsDOI 10.1371/journal.pone.0236642

1,021 patientsAmong the 1,754 patients, 1,021 were HIV-2 infected.

Côte d'IvoireVIH/sidapublished 2013PloS oneeurope_pmcdocument of 14 observations

29 %Among hospitalized HIV-positive adults in West Africa, tuberculosis was the most frequent disease diagnosed, occurring in 29% of patients.

Côte d'Ivoiretuberculose · VIH/sidaobserved 2010published 2014Journal of the International AIDS Societyeurope_pmcdocument of 22 observationsDOI 10.7448/ias.17.1.18797